Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Jin, Young Joo ^a   Lee, Jin Woo ^a,b,p   Lee, Jung il ^a   Park, Sang Hoon ^b   Park, Choong Kee ^c   Kim, Young Seok ^c   Jeong, Sook Hyang ^d   Kim, Yun Soo ^e   Kim, Ju Hyun ^e   Hwang, Seong Gyu ^f   Rim, Kyu Sung ^f   Yim, Hyung Joon ^g   Cheong, Jae Youn ^h   Cho, Sung Won ^h   Lee, June Sung ⁱ   Park, Young Min ^j   Jang, Jeong Won ^k   Lee, Chun Kyon ^l   Sohn, Joo Hyun ^m   Yang, Jin Mo ⁿ   Han, Seungbong ^o   more..

^a Department of Internal Medicine ^*  (South Korea)

^b Inha University School of Medicine   (South Korea)

^c Hallym University   (South Korea)

^d Soonchunhyang University College of Medicine   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

^f Gachon University   (South Korea)

^g CHA University   (South Korea)

^h Korea University College of Medicine   (South Korea)

ⁱ Ajou University School of Medicine   (South Korea)

^j Inje University College of Medicine   (South Korea)

^k Bundang Jesaeng Hospital   (South Korea)

^l The Catholic University of Korea   (South Korea)

^m National Health Insurance Corporation   (South Korea)

ⁿ Hanyang University Guri Hospital   (South Korea)

^o University of Ulsan College of Medicine   (South Korea)

^p Inha University Hospital   (South Korea)

more..

Author keywords

Chronic hepatitis C; Pegylated interferon alfa 2a; Pegylated interferon alfa 2b; Ribavirin; Sustained virological response

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALOPECIA; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; ETHNIC GROUP; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION; KOREAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTE; VIRUS LOAD; VIRUS TYPING;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RIBAVIRIN; VIRAL LOAD;

EID: 84876789373     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-74     Document Type: Article

References (33)

1. Williams R. Global challenges in liver disease. Hepatology 2006, 44:521-526. 10.1002/hep.21347, 16941687.
2. McCaughan GW, Omata M, Amarapurkar D. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007, 22:615-633.
3. Perz JF, Armstrong GL, Farrington LA. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45:529-538. 10.1016/j.jhep.2006.05.013, 16879891.
4. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002, 36:S30-S34.
5. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374. 10.1002/hep.22759, 19330875.
6. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264.
7. Manns MP, McHutchison JG, Gordon SC. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965. 10.1016/S0140-6736(01)06102-5, 11583749.
8. Fried MW, Shiffman ML, Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982. 10.1056/NEJMoa020047, 12324553.
9. Silva M, Poo J, Wagner F. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006, 45:204-213. 10.1016/j.jhep.2006.03.008, 16780997.
10. Bruno R, Sacchi P, Scagnolari C. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naive patients with chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol Ther 2007, 26:369-376. 10.1111/j.1365-2036.2007.03392.x, 17635371.
11. McHutchison JG, Lawitz EJ, Shiffman ML. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593. 10.1056/NEJMoa0808010, 19625712.
12. Laguno M, Cifuentes C, Murillas J. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009, 49:22-31. 10.1002/hep.22598, 19085908.
13. Ascione A, De Luca M, Tartaglione MT. Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection. Gastroenterology 2010, 138:116-122. 10.1053/j.gastro.2009.10.005, 19852964.
14. Rumi MG, Aghemo A, Prati GM. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010, 138:108-115. 10.1053/j.gastro.2009.08.071, 19766645.
15. Awad T, Thorlund K, Hauser G. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010, 51:1176-1184. 10.1002/hep.23504, 20187106.
16. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009, 24:336-345. 10.1111/j.1440-1746.2009.05789.x, 19335784.
17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293. 10.1002/hep.510240201, 8690394.
18. McHutchison JG, Manns M, Patel K. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069. 10.1053/gast.2002.35950, 12360468.
19. Miyase S, Haraoka K, Ouchida Y. Randomized trial of peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin for chronic hepatitis C in Japanese patients. J Gastroenterol 2012,
20. Zhao S, Liu E, Yu H. Comparison of peginterferon and interferon in treating Chinese patients with chronic hepatitis C. Hepatogastroenterology 2008, 55:1047-1054.
21. Lee S, Kim IH, Kim SH. Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology 2010, 53:146-153. 10.1159/000274975, 20068348.
22. Fujino T, Nakamuta M, Aoyagi Y. Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin. Med Sci Monit 2011, 17:CR687-691. 10.12659/MSM.882127, 3628125, 22129899.
23. Ge D, Fellay J, Thompson AJ. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401. 10.1038/nature08309, 19684573.
24. Yu ML, Huang CF, Huang JF. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011, 53:7-13. 10.1002/hep.23976, 21254157.
25. Thomas DL, Thio CL, Martin MP. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801. 10.1038/nature08463, 3172006, 19759533.
26. Jensen DM, Morgan TR, Marcellin P. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43:954-960. 10.1002/hep.21159, 16628671.
27. Poordad F, McCone J, Bacon BR. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206. 10.1056/NEJMoa1010494, 21449783.
28. Jacobson IM, McHutchison JG, Dusheiko G. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416. 10.1056/NEJMoa1012912, 21696307.
29. Ferenci P. Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 2004, 24(Suppl 2):25-31.
30. Ferenci P, Fried MW, Shiffman ML. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005, 43:425-433. 10.1016/j.jhep.2005.04.009, 15990196.
31. Hadziyannis SJ, Sette H, Morgan TR. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
32. Maynard M, Pradat P, Gagnieu MC. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 2008, 13:607-611.
33. Shiffman ML, Ghany MG, Morgan TR. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007, 132:103-112. 10.1053/j.gastro.2006.11.011, 17241864.